Can a common supplement curb stroke damage?

NCT ID NCT07749287

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This phase 3 trial investigates whether N-acetyl cysteine (NAC), an antioxidant supplement, can improve recovery in people hospitalized with an acute ischemic stroke. Participants receive either NAC or a placebo (saline) shortly after admission, and researchers track their neurological function and markers of inflammation. The goal is to see if NAC can reduce stroke-related disability and dampen the body's harmful inflammatory response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
N-acetyl cysteine (NAC) given as a 600 mg oral solution every 8 hours for 3 days after hospital admission
What this could lead to
If NAC proves effective, it could offer a simple, widely available treatment to improve recovery and reduce disability after an acute ischemic stroke.
What could go wrong
This is a single-center trial with a modest number of participants, and results may not generalize. NAC's benefits beyond standard care remain uncertain, and it is not a replacement for clot-busting drugs when those are appropriate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stroke Unit, Neurology Department, Kasr Al Ainy, Cairo University Hospital

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.